Literature DB >> 15013487

Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice.

Michael R Lewis1, Jiuli Zhang, Fang Jia, Nellie K Owen, Cathy S Cutler, Mary F Embree, Jody Schultz, Louis J Theodore, Alan R Ketring, Silvia S Jurisson, Donald B Axworthy.   

Abstract

The radiolanthanides (149)Pm, (166)Ho, and (177)Lu possess a range of half-lives and alpha(-) beta(-) energies for targeted radiotherapy of cancer. (149)Pm-, (166)Ho-, and (177)Lu-DOTA-biotin were pretargeted to LS174T colorectal tumors in nude mice with CC49 scFvSA antibody-streptavidin fusion protein. Tumor uptakes of (149)Pm (22.9% ID/g), (166)Ho (30.2% ID/g), and (177)Lu (35.4% ID/g) peaked at 1-4 h. Rapid blood disappearance was accompanied by urinary excretion of 59-66% ID within 1 h. Biodistributions of these agents show promise for pretargeted radioimmunotherapy of cancer.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15013487     DOI： 10.1016/j.nucmedbio.2003.08.004

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN： 0969-8051            Impact factor:   2.408


  8 in total

Review 1.  Continuing pursuit for ideal systemic anticancer radiotherapeutics.

Authors:  Marlein Miranda Cona; Huaijun Wang; Junjie Li; Yuanbo Feng; Feng Chen; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  Invest New Drugs       Date:  2011-10-18       Impact factor: 3.850

2.  Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).

Authors:  Nicoletta Urbano; Stefano Papi; Mauro Ginanneschi; Rita De Santis; Silvia Pace; Ragnar Lindstedt; Liliana Ferrari; Sunju Choi; Giovanni Paganelli; Marco Chinol
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-06       Impact factor: 9.236

3.  166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: comparison with 188Re radiolabel.

Authors:  S Thompson; B Ballard; Z Jiang; E Revskaya; N Sisay; W H Miller; C S Cutler; E Dadachova; L C Francesconi
Journal:  Nucl Med Biol       Date:  2013-12-30       Impact factor: 2.408

Review 4.  Cutting edge rare earth radiometals: prospects for cancer theranostics.

Authors:  Alexander W E Sadler; Leena Hogan; Benjamin Fraser; Louis M Rendina
Journal:  EJNMMI Radiopharm Chem       Date:  2022-08-26

5.  N-acetylgalactosamino dendrons as clearing agents to enhance liver targeting of model antibody-fusion protein.

Authors:  Barney Yoo; Sarah M Cheal; Geralda Torchon; Anna Dilhas; Guangbin Yang; Jun Pu; Blesida Punzalan; Steven M Larson; Ouathek Ouerfelli
Journal:  Bioconjug Chem       Date:  2013-11-18       Impact factor: 4.774

6.  Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.

Authors:  Sofia H L Frost; Shani L Frayo; Brian W Miller; Johnnie J Orozco; Garrett C Booth; Mark D Hylarides; Yukang Lin; Damian J Green; Ajay K Gopal; John M Pagel; Tom A Bäck; Darrell R Fisher; Oliver W Press
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

Review 7.  Therapeutic Applications of Pretargeting.

Authors:  Marjolein Verhoeven; Yann Seimbille; Simone U Dalm
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

8.  Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy.

Authors:  Michiel Van de Voorde; Charlotte Duchemin; Reinhard Heinke; Laura Lambert; Eric Chevallay; Thomas Schneider; Miranda Van Stenis; Thomas Elias Cocolios; Thomas Cardinaels; Bernard Ponsard; Maarten Ooms; Thierry Stora; Andrew R Burgoyne
Journal:  Front Med (Lausanne)       Date:  2021-07-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.